



IAP4 Rec'd PCT/PTO 18 NOV 2005
PCT
307-5eq

MUR-025-USA-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
H. Arima, et al.

Serial No.: 09/720,363

Art Unit: To Be Assigned

Filed: December 22, 2000

Examiner: To Be Assigned

For: Antisense Oligonucleotide Inhibiting IL-10 Protein Expression

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE PURSUANT TO
37 C.F.R. 1.821, 1.822, 1.825 and 1.832**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Notification of Defective Response mailed on September 15, 2005, in the above identified application, submitted herewith in the above identified pending U.S. Patent Application is the following:

1. A computer readable form (CRF) copy of the "Sequence Listing";
2. An initial paper copy of the "Sequence Listing"; and

The undersigned hereby states that the content of the CRF copy and the initial paper copy of the Sequence Listing, as attached hereto, submitted in accordance with 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) and 1.825(d), respectively, contain no new matter, and contain the same Sequence Listings as originally filed in the case in written and/or CRF format. The attached CRF and paper copy is filed merely to place the Sequence Listings in a form complying with the

requirements listed above. It is hereby respectfully requested that the attached CRF and paper copy of the "Sequence Listing" be entered into the specification.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Donald E. Townsend, Jr.
Donald E. Townsend, Jr.
Reg. No. 43,198

Date: November 15, 2005

TOWNSEND & BANTA
Suite 900, South Building
601 Pennsylvania Ave., N.W.
Washington, D.C. 20004
(202) 220-3124



CERTIFICATE OF MAILING


I hereby certify that this correspondence, consisting of this Submission, a paper copy of the "Sequence Listing", and a CRF copy of the "Sequence Listing", is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On November 15, 2005.

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.



80149.078 US1

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/720,363	Hidetoshi Arima	MUR-025-USA-PCT
INTERNATIONAL APPLICATION NO.		
PCT/JP99/03315		
LA. FILING DATE	PRIORITY DATE	
06/22/1999	06/24/1998	

27955
TOWNSEND & BANTA
c/o PORTFOLIO IP
PO BOX 52050
MINNEAPOLIS, MN 55402

SEQ. LISTING
11/15/05 - 2 MO
D- 04/15/06 - 7 MO
FINAL

CONFIRMATION NO. 9423
371 FORMALITIES LETTER



OC000000017005289

Date Mailed: 09/15/2005


NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov



SEQL-1

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/720,363	PCT/JP99/03315	MUR-025-USA-PCT

FORM PCT/DO/EO/922 (371 Formalities Notice)